Senseonics/Roche Renew Distribution Agreement; Acquisition Unlikely

Senseonics announced it has come to an agreement with Roche to extend the existing distribution agreement for the Eversense implantable CGM. Additionally, Senseonics held an investor webcast to discuss the updated agreement. Below, FENIX provides a summary of the webcast as well as thoughts on why it may have made more sense for Roche to extend the partnership than to outright buy Senseonics.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.